Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis

BACKGROUND: Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib...

Descripción completa

Detalles Bibliográficos
Autores principales: Senoo, Satoru, Miyahara, Nobuaki, Taniguchi, Akihiko, Oda, Naohiro, Itano, Junko, Higo, Hisao, Hara, Naofumi, Watanabe, Hiromi, Kano, Hirohisa, Suwaki, Toshimitsu, Fuchimoto, Yasuko, Kajimoto, Kazuhiro, Ichikawa, Hirohisa, Kudo, Kenichiro, Shibayama, Takuo, Tanimoto, Yasushi, Kuyama, Shoichi, Kanehiro, Arihiko, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451511/
https://www.ncbi.nlm.nih.gov/pubmed/32853277
http://dx.doi.org/10.1371/journal.pone.0236935

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451511/
https://www.ncbi.nlm.nih.gov/pubmed/32853277
http://dx.doi.org/10.1371/journal.pone.0236935

Ejemplares similares